{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:13:08Z","timestamp":1791313988180,"version":"4.3.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00520-024-08367-9","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T04:02:01Z","timestamp":1708747321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea"],"prefix":"10.1007","volume":"32","author":[{"given":"Ryugyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhee","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Kyung","family":"Je","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"issue":"5","key":"8367_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00434947","volume":"1","author":"C Lindley","year":"1992","unstructured":"Lindley C, Hirsch J, O\u2019Neill C, Transau M, Gilbert C, Osterhaus J (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1(5):331\u2013340","journal-title":"Qual Life Res"},{"issue":"4","key":"8367_CR2","doi-asserted-by":"publisher","first-page":"E133","DOI":"10.1188\/12.CJON.E133-E141","volume":"16","author":"PH Viale","year":"2012","unstructured":"Viale PH, Grande C, Moore S (2012) Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 16(4):E133\u2013E141","journal-title":"Clin J Oncol Nurs"},{"issue":"7","key":"8367_CR3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","volume":"16","author":"AJ Wozniak","year":"1998","unstructured":"Wozniak AJ, Crowley JJ, Balcerzak SP et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16(7):2459\u20132465","journal-title":"J Clin Oncol"},{"issue":"5","key":"8367_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, De Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting\u2014incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503","journal-title":"Support Care Cancer"},{"key":"8367_CR5","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Antiemesis. Version 2.2022.  Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf.  Accessed March 23 2022"},{"issue":"1083","key":"8367_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/postgradmedj-2014-132969","volume":"92","author":"N Tageja","year":"2016","unstructured":"Tageja N, Groninger H (2016) Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J 92(1083):34\u201340","journal-title":"Postgrad Med J"},{"issue":"1","key":"8367_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103\u2013109","journal-title":"J Clin Oncol"},{"issue":"2","key":"8367_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000421-199604000-00023","volume":"19","author":"GR Morrow","year":"1996","unstructured":"Morrow GR, Hickok JT, Burish TG, Rosenthal SN (1996) Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol 19(2):199\u2013203","journal-title":"Am J Clin Oncol"},{"key":"8367_CR9","doi-asserted-by":"crossref","unstructured":"Navari RM (2015) Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int\u00a02015:595894","DOI":"10.1155\/2015\/595894"},{"issue":"1","key":"8367_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.14694\/EdBook_AM.2012.32.230","volume":"32","author":"E Basch","year":"2012","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Somerfield MR, Lyman GH (2012) Antiemetic use in oncology: updated guideline recommendations from ASCO. Am Soc Clin Oncol Educ Book 32(1):532\u2013540","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"14 Suppl","key":"8367_CR11","first-page":"S259","volume":"23","author":"N Adel","year":"2017","unstructured":"Adel N (2017) Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Managed Care 23(14 Suppl):S259\u2013S265","journal-title":"Am J Managed Care"},{"issue":"1","key":"8367_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27(1):87\u201395","journal-title":"Support Care Cancer"},{"issue":"2","key":"8367_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134\u2013142","journal-title":"N Engl J Med"},{"key":"8367_CR14","unstructured":"Health Insurance Review and Assessment Service (2020) Detailes on the application standards and methods of prescription drug coverage for cancer patients. Available from: https:\/\/repository.hira.or.kr\/handle\/2019.oak\/2526"},{"issue":"4","key":"8367_CR15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.4143\/crt.2015.309","volume":"48","author":"MA Lee","year":"2016","unstructured":"Lee MA, Cho EK, Oh SY et al (2016) Clinical practices and outcomes on chemotherapy-induced nausea and vomiting management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study. Cancer Res Treat 48(4):1420\u20131428","journal-title":"Cancer Res Treat"},{"key":"8367_CR16","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1002\/onco.13716","volume":"26","author":"M Aapro","year":"2021","unstructured":"Aapro M, Scott\u00e9 F, Escobar Y et al (2021) Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 26:e1073\u2013e1082","journal-title":"Oncologist"},{"key":"8367_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00520-014-2372-3","volume":"23","author":"S Yu","year":"2015","unstructured":"Yu S, Burke TA, Chan A et al (2015) Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy\u2014a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer 23:273\u2013282","journal-title":"Support Care Cancer"},{"key":"8367_CR18","unstructured":"Health Insurance Review and Assessment Service (2016) Guidelines for revision of notice on medications prescribed and administered to cancer patients. Available from: https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA030023010000&brdScnBltNo=4&brdBltNo=45528&pageIndex=9&pageIndex2=9#none"},{"issue":"5","key":"8367_CR19","first-page":"273","volume":"8","author":"L Schwartzberg","year":"2015","unstructured":"Schwartzberg L, Harrow B, Lal LS, Radtchenko J, Lyman GH (2015) Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens. Am Health Drug Benefits 8(5):273\u2013282","journal-title":"Am Health Drug Benefits"},{"key":"8367_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.6004\/jnccn.2019.7526","volume":"18","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Ruddy KJ, LeBlanc TW et al (2020) What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. J Natl Compr Canc Netw 18:676\u2013681","journal-title":"J Natl Compr Canc Netw"},{"key":"8367_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839\u2013848","journal-title":"J Pain Symptom Manage"},{"key":"8367_CR22","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260\u20131267","journal-title":"Ann Oncol"},{"key":"8367_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2217\/fon.14.260","volume":"11","author":"V Lorusso","year":"2015","unstructured":"Lorusso V, Karthaus M, Aapro M (2015) Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting. Future Oncol 11:565\u2013577","journal-title":"Future Oncol"},{"key":"8367_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/TCRM.S89215","volume":"12","author":"V Lorusso","year":"2016","unstructured":"Lorusso V (2016) Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant\/palonosetron. Ther Clin Risk Manag 12:917","journal-title":"Ther Clin Risk Manag"},{"key":"8367_CR25","doi-asserted-by":"publisher","first-page":"24402","DOI":"10.18632\/oncotarget.8255","volume":"7","author":"Q Shi","year":"2016","unstructured":"Shi Q, Li W, Li H et al (2016) Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison. Oncotarget 7:24402","journal-title":"Oncotarget"},{"key":"8367_CR26","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986\u20131992","journal-title":"Ann Oncol"},{"key":"8367_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JOP.2012.000816","volume":"10","author":"JW Gilmore","year":"2014","unstructured":"Gilmore JW, Peacock NW, Gu A et al (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. Journal of oncology practice 10:68\u201374","journal-title":"Journal of oncology practice"},{"key":"8367_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","volume":"16","author":"A Molassiotis","year":"2008","unstructured":"Molassiotis A, Saunders MP, Valle J et al (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201\u2013208","journal-title":"Support Care Cancer"},{"key":"8367_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-018-1199-z","volume":"35","author":"M Karayama","year":"2018","unstructured":"Karayama M, Inui N, Tanaka K et al (2018) Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis. Med Oncol 35:1\u20137","journal-title":"Med Oncol"},{"key":"8367_CR30","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1200\/JCO.2003.08.118","volume":"21","author":"WC Mertens","year":"2003","unstructured":"Mertens WC, Higby DJ, Brown D et al (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21:1373\u20131378","journal-title":"J Clin Oncol"},{"key":"8367_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00520-003-0553-6","volume":"12","author":"F Roila","year":"2004","unstructured":"Roila F (2004) Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 12:446\u2013453","journal-title":"Support Care Cancer"},{"key":"8367_CR32","first-page":"20","volume":"17","author":"F Roila","year":"2005","unstructured":"Roila F, Hesketh PJ, Herrstedt J (2005) Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Annals Oncol Off J Eur Soc Med Oncol 17:20\u201328","journal-title":"Annals Oncol Off J Eur Soc Med Oncol"},{"key":"8367_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1200\/JCO.1998.16.2.771","volume":"16","author":"MJ Nolte","year":"1998","unstructured":"Nolte MJ, Berkery R, Pizzo B et al (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16:771\u2013778","journal-title":"J Clin Oncol"},{"key":"8367_CR34","doi-asserted-by":"publisher","first-page":"e1127","DOI":"10.1002\/cnr2.1127","volume":"1","author":"M Aapro","year":"2018","unstructured":"Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V (2018) Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep 1:e1127","journal-title":"Cancer Rep"},{"key":"8367_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12890-023-02524-2","volume":"23","author":"T Ide","year":"2023","unstructured":"Ide T, Nishino Y, Takiguchi T et al (2023) Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region. BMC Pulm Med 23:228","journal-title":"BMC Pulm Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08367-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08367-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08367-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T05:21:42Z","timestamp":1710825702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08367-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["8367"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08367-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3294277\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board (IRB) of Pusan National University, Busan, Korea (PNU IRB\/2022_116_HR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}